GoodRx Holdings, Inc. (NASDAQ:GDRX) Financial Performance and Industry Comparison

• GoodRx Holdings, Inc. (NASDAQ:GDRX) showcases a positive ROIC to WACC ratio of 1.11, indicating efficient capital utilization.
• American Well Corporation and other competitors like JFrog Ltd. (FROG) and Asana, Inc. (ASAN) display negative ROIC to WACC ratios, suggesting challenges in generating returns above their cost of capital.
• Doximity, Inc. (DOCS) outperforms GoodRx and its peers with a ROIC to WACC ratio of 1.54, highlighting superior capital efficiency.

GoodRx Holdings, Inc. (NASDAQ:GDRX) is a company that provides a platform to compare prescription drug prices and offers discounts on medications. It operates in the healthcare sector, focusing on making medications more affordable for consumers. GoodRx competes with other companies in the digital health and telemedicine space, such as American Well Corporation and Doximity, Inc.

In evaluating GoodRx's financial performance, the Return on Invested Capital (ROIC) is 10.56%, while the Weighted Average Cost of Capital (WACC) is 9.53%. This results in a ROIC to WACC ratio of 1.11, indicating that GoodRx is generating returns above its cost of capital. This is a positive indicator for investors, as it suggests efficient capital utilization.

Comparatively, American Well Corporation (AMWL) shows a ROIC of -65.81% against a WACC of 8.75%, resulting in a ROIC to WACC ratio of -7.52. This negative ratio suggests that American Well is not generating sufficient returns to cover its cost of capital, which may be concerning for investors.

JFrog Ltd. (FROG) and Asana, Inc. (ASAN) also exhibit negative ROIC to WACC ratios of -1.27 and -8.55, respectively. These figures indicate that both companies are struggling to generate returns that exceed their cost of capital, which could impact their financial health and investor confidence.

Doximity, Inc. (DOCS) stands out with a ROIC of 15.99% and a WACC of 10.39%, resulting in a ROIC to WACC ratio of 1.54. This suggests that Doximity is highly efficient in generating returns on its invested capital, outperforming its peers, including GoodRx, in terms of capital utilization.